SYL1001 de Sylentis ( Grupo PharmaMar ) Inicia la Fase III . Un Ensayo del que se Podría Resultados a Finales del 2018 .

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED) .

Status Recruiting

*.- Last follow-up date : 2018-12 (Anticipated)

*.- Primary completion date : 2018-03 (Anticipated).

*.- Sponsor : Sylentis, S.A.